Medivir AB (STU:MVR0)
€ 0.27 0.009 (3.45%) Market Cap: 32.22 Mil Enterprise Value: 18.56 Mil PE Ratio: 0 PB Ratio: 2.07 GF Score: 47/100

Q3 2023 Medivir AB Earnings Call Transcript

Oct 27, 2023 / 12:00PM GMT
Release Date Price: €0.481221 (-8.62%)
Jens Lindberg
Medivir AB - CEO

Welcome, everyone to the Medivir Q3 report. Today is a very exciting day. In addition to sharing the great progress and continued momentum in the ongoing Fostrox program, it is with great enthusiasm we look forward to providing an in-depth update on the promising signals of clinical benefit we're seeing with the Fostrox-Lenvima combination in primary liver cancer, and we will also touch on what that means for our plans as we move ahead.

Before we go into the details, as always, important information and this, in detail, you will find when we post the presentation on our website. My name is Jens Lindberg, and I am the CEO of Medivir. Today, I am joined by our Chief Medical Officer, Pia Baumann, and our CFO, Magnus Christensen. Our Chief Scientific Officer, Fredrik Ãberg, is also here with us for the Q&A session towards the end.

But most importantly, we are joined by Dr. Jeff Evans from Glasgow, Scotland, who is principal investigator in the ongoing Fostrox-Lenvima study. Jeff is joining us via link today from Scotland where he is working clinically

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot